Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 979
countries
28
conditions
2 106

27 trials match your criteria

Anti-myelin-associated glycoprotein associated polyneuropathy

Recruiting

Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Plasma cell myeloma refractory+1

Not yet recruiting

Dose optimization study of ibrutinib drug combination in adult patients with haematological diseases

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab

Waldenstrom's macroglobulinaemia+1

Not recruiting

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Chronic lymphocytic leukaemia

Not recruiting

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Untreated Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Follicular lymphoma

Not recruiting

Study of Mosunetuzumab and Zanubrutinib for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Cold type haemolytic anaemia

Not recruiting

Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Splenic marginal zone lymphoma

Not recruiting

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Chronic lymphocytic leukaemia

Not recruiting

Study on Bendamustine, Obinutuzumab, Zanubrutinib, and Venetoclax for Patients with Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.